Press Releases
Samsung Biologics hosts ‘Biopharma Safety and Health Forum’
![[????????]%20????%20????%20??%20??--01.png](/upload/editor/20240430121144Bebec3b7f-cd32-4c76-a70d-ae5a67afaf97.png)
Samsung Biologics hosted the first ‘Biopharma Safety and Health Forum,’ inviting the public and private sector to discuss measures to strengthen workplace safety and health.
The forum, the first of its kind, brought together officials from Korea’s labor ministry and occupational safety and health agency, as well as 11 biopharma companies, to discuss the government’s health and safety policies. Samsung Biologics shared its expertise in process safety management and successful case studies regarding the establishment of health-related infrastructure for employees.
“We held in-depth discussions on ways to bolster safety and health management at local biopharma companies,” said Kun Lo, Executive Vice President of Engineering, Procurement, Construction, and Validation (EPCV) at Samsung Biologics. “Based on the insights shared, we look forward to the implementation of activities and policies suited for each company.”
Samsung Biologics will host two more sessions in the latter of this year, while the labor ministry plans to provide incentives to biopharma companies that take part.
Samsung Biologics hosted the first ‘Biopharma Safety and Health Forum,’ inviting the public and private sector to discuss measures to strengthen workplace safety and health.
The forum, the first of its kind, brought together officials from Korea’s labor ministry and occupational safety and health agency, as well as 11 biopharma companies, to discuss the government’s health and safety policies. Samsung Biologics shared its expertise in process safety management and successful case studies regarding the establishment of health-related infrastructure for employees.
“We held in-depth discussions on ways to bolster safety and health management at local biopharma companies,” said Kun Lo, Executive Vice President of Engineering, Procurement, Construction, and Validation (EPCV) at Samsung Biologics. “Based on the insights shared, we look forward to the implementation of activities and policies suited for each company.”
Samsung Biologics will host two more sessions in the latter of this year, while the labor ministry plans to provide incentives to biopharma companies that take part.